← Search another drug
PatientPulse · by PatientPartner
Leqembi lecanemab
Moderate confidence
~54 public patient conversations, forum threads, and news narratives referenced; Drugs.com review count = 6 verified; all other volume estimates are corpus-based analyst assessments.
Executive intelligence
The signal that moves starts & adherence
38%Positive sentiment in discussion
3,327FDA adverse-event reports
41%Flagged serious
59%Reports name female patients
Access friction (not safety fear) is the single biggest adoption killer: a 10-week prescription-to-needle lag is the norm, and only 16% of eligible patients at major centers ultimately start treatment.
- Access barriers (amyloid confirmation, registry enrollment, infusion-site logistics, and insurance battles) are cited more often than side-effect fear as the primary reason eligible patients delay or decline Leqembi.
- Patients and caregivers consistently report that the drug's benefit is invisible in daily life, creating a persistent adherence-threatening uncertainty best summarized as 'it may be helping, but I can't tell.'
- Infusion-related reactions and post-infusion headache, fatigue, and chills drive early discontinuation, while a vocal minority of long-term users (40+ infusions) report tolerating the regimen well after the first few doses.
- The Leqembi vs. Kisunla decision is now the dominant pre-treatment conversation, with patients weighing infusion frequency, ARIA risk by APOE4 status, cost differences, and the prospect of a finite Kisunla treatment course.